Institutional Review Boards (IRBs) and Institutional Animal Care and Use Committees (IACUCs) are the two oversight bodies that sit between a researcher’s idea and its execution, making sure that studies involving people or animals meet ethical and legal standards before a single participant is enrolled or a single animal is housed. Every university, hospital, and research institute in the United States that receives federal funding is required to maintain one or both. They are not rubber stamps: these committees have the authority to approve, require changes to, or reject research protocols outright. Understanding how they work, where they came from, and where they sometimes fall short matters for anyone involved in research or affected by its results.
Why These Committees Exist
The modern system of research ethics oversight in the United States traces directly to a series of scandals. Between the 1950s and mid-1970s, numerous cases of unethical human experimentation came to light. The most notorious was the Tuskegee Syphilis Study, revealed publicly in 1972, in which hundreds of Black men in Alabama were deliberately left untreated for syphilis for 40 years so researchers could observe the disease’s progression.1PubMed Central. The Belmont Report at 40: Reckoning With Time Tuskegee was not an isolated case, but it was the one that made it impossible for lawmakers to keep trusting existing codes like the Nuremberg Code and the Declaration of Helsinki to prevent abuses on their own.
Congress responded with the National Research Act of 1974, which created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.2PubMed. The historical, ethical, and legal background of human-subjects research That commission’s most lasting product was the Belmont Report, which laid out a principled framework for resolving ethical problems in human-subjects research.1PubMed Central. The Belmont Report at 40: Reckoning With Time The Belmont Report established three core principles: respect for persons (people must give informed, voluntary consent), beneficence (researchers must maximize potential benefits and minimize harms), and justice (the burdens and benefits of research must be distributed fairly). These three principles remain the ethical backbone of every IRB review today.
Animal research oversight followed a parallel but distinct path. In 1959, two British researchers, William Russell and Rex Burch, published a framework known as the Three Rs: Replacement (use alternatives to animals when possible), Reduction (use the fewest animals necessary), and Refinement (minimize pain and distress).3PubMed Central. The 3Rs and Humane Experimental Technique: Implementing Change These principles were eventually codified into U.S. law through the Animal Welfare Act and the Public Health Service Policy on Humane Care and Use of Laboratory Animals, both of which require institutions to establish IACUCs.
Who Sits on These Committees
Neither an IRB nor an IACUC is meant to be a club of like-minded scientists reviewing each other’s work. Federal regulations require both committees to include members from outside the research community, specifically to bring perspectives that scientists themselves might miss.
For IRBs, the rules mandate at least one member whose primary concerns are in nonscientific areas and at least one member who is not affiliated with the institution.4PubMed. A qualitative study of non-affiliated, non-scientist institutional review board members In practice, that unaffiliated member is often a community volunteer, a clergy member, a lawyer, or someone with patient-advocacy experience. The nonscientist member ensures that consent forms, for example, are written in language an average person can actually understand rather than in dense medical jargon.
IACUCs have a similar structure but with an explicit veterinary requirement. Under the Public Health Service Policy, an IACUC must have at least five members: a chairperson, a veterinarian with program authority, a practicing scientist experienced in animal research, a member with primarily nonscientific concerns, and a member not affiliated with the institution. The Animal Welfare Act regulations set a lower floor of at least three members, including a veterinarian and an unaffiliated member.5Oxford Academic (ILAR Journal). The Role of IACUCs in Responsible Animal Research The veterinarian’s role is especially important because they can assess whether a proposed procedure is likely to cause pain, whether the analgesia plan is adequate, and whether the housing and care standards are appropriate for the species involved.
How Review Actually Works
Not every study gets the same level of scrutiny, and the system is designed that way on purpose. IRBs sort incoming protocols into tiers. Some research is exempt from full board review, typically studies involving publicly available data, normal educational practices, or anonymous surveys that carry minimal risk. Other studies qualify for expedited review, handled by one or two experienced committee members rather than the full board. Only research involving more than minimal risk to participants goes before the full committee for discussion and a vote.
Getting that sorting right matters. A study of 313 protocols at one institution found strong agreement between how protocols were classified and how they should have been classified according to federal criteria for full-board reviews (about 98% agreement) and expedited reviews (about 94% agreement). But for exempt studies, agreement dropped to 75%, with roughly one in six protocols classified as exempt actually requiring some level of IRB review.6SAGE Journals / PubMed Central. Assessing the Quality and Performance of Institutional Review Boards: Levels of Initial Reviews That gap is a real vulnerability in the system, because exempt studies receive the least oversight.
IACUC review operates somewhat differently. Every protocol involving live vertebrate animals must be reviewed and approved before the work begins, and protocols typically come up for renewal annually or every three years depending on the institution and regulation. The committee evaluates the scientific justification for using animals, the species and number requested, the procedures involved, the pain management plan, and the endpoint criteria (the point at which an animal in distress will be humanely euthanized). IACUCs also conduct unannounced inspections of animal facilities at least twice a year, which gives them teeth that IRBs generally lack. An IRB reviews paperwork; an IACUC reviews paperwork and walks through the lab.
The Informed Consent Problem
One of the IRB’s primary responsibilities is ensuring that people enrolled in research give genuinely informed consent. That means participants should understand what the study involves, what risks they face, and what benefits they might receive. In practice, the documents meant to accomplish this are often a mess. A review of 172 informed consent documents for early-phase clinical trials found that while about 83% described the types of health risks involved, only about a third described how severe those risks might be. The situation was worse on the benefit side: fewer than half specified what the potential health benefits actually were, and none of them quantified how likely those benefits were to occur.7PubMed Central. Details of risk–benefit communication in informed consent documents for phase I/II trials
Even when consent forms did include likelihood information for risks, the presentation was inconsistent. Only about 57% attached actual numbers to words like “common” or “rare,” and the frequency ranges assigned to those words varied widely between documents.7PubMed Central. Details of risk–benefit communication in informed consent documents for phase I/II trials A participant reading that a side effect is “rare” in one trial might face a different probability than a participant reading “rare” in another trial, with no way to know the difference. This is not a failure of individual researchers so much as a systemic gap: IRBs approve these documents, and yet the standards for how risk and benefit should be communicated remain vague enough that wildly different approaches all pass muster.
Inconsistency Across Institutions
One of the most persistent criticisms of both IRBs and IACUCs is that the same protocol can receive very different treatment depending on which institution reviews it. A review of 52 studies examining IRB operations found that IRBs presented with identical protocols sometimes requested different revisions, and in some cases, the revisions requested by different boards directly contradicted each other.8PubMed Central. Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform For researchers running studies at multiple sites, this created a practical nightmare: satisfying one IRB’s demands could mean violating another’s.
The same review found that waiting for IRB approval delayed some projects, that IRBs operated at different levels of efficiency, and that some committee decisions were not consistent with federal policy guidance.8PubMed Central. Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform These are not minor annoyances. In time-sensitive research, such as during disease outbreaks, delays of weeks or months can mean the difference between generating useful evidence and arriving too late to matter.
IACUCs face their own version of this challenge, especially around pain management. Assessing how much pain an animal experiences during a procedure is genuinely difficult. Current tools for measuring pain severity across different species and strains are limited, pain diagnosis in animals is inherently imprecise, and the effects of pain medications on research data are not always well understood.9PubMed Central. Ethical and IACUC Considerations Regarding Analgesia and Pain Management in Laboratory Rodents Different committees can look at the same procedure and reach different conclusions about whether the analgesic plan is adequate, because the underlying science of animal pain assessment is still evolving.
The Single IRB Solution for Multisite Research
To address the inconsistency problem for studies conducted across many hospitals or universities, the National Institutes of Health adopted a policy requiring the use of a single IRB for multisite research. The goal was straightforward: rather than having the same protocol reviewed by 15 different IRBs at 15 different sites, one designated IRB would serve as the board of record for the entire study.10PubMed Central. Reliance agreements and single IRB review of multisite research: Concerns of IRB members and staff
In principle, this saves enormous amounts of time and eliminates conflicting demands. In practice, it has raised its own set of concerns. Some IRB members and staff worry about losing local oversight. A centralized IRB in one state may not fully understand the community context at a research site in another, including local cultural norms, the demographics of the participant population, and the specific vulnerabilities of that community. Reliance agreements between institutions, the legal documents that let one IRB defer to another, also create questions about liability and accountability when something goes wrong. The policy solved one problem and surfaced others that are still being worked out.
The Vulnerable Populations Paradox
Both IRBs and IACUCs exist to protect subjects from harm, but protection can itself become a source of harm when it goes too far. Certain groups of people, including children, pregnant women, prisoners, and people with cognitive impairments, are classified as “vulnerable populations” and receive extra layers of ethical safeguard. Research involving these groups faces stricter scrutiny, additional consent requirements, and sometimes outright prohibition of certain study designs.
The paradox is that limiting research on these populations can leave them medically underserved. If you cannot test a drug in children because the ethical barriers are too high, children end up receiving medications dosed and prescribed based on adult data, which may not work the same way in their bodies. Current ethical guidelines that prohibit or severely limit research on vulnerable populations may protect those populations in the short term while limiting their access to therapies that could save their lives in the long term.11ScienceDirect. Clinical research: protection of the “vulnerable”? Finding the right balance, enough protection to prevent exploitation without so much restriction that it perpetuates medical neglect, is one of the harder problems in research ethics, and one that different IRBs handle differently.
When Oversight Becomes Over-Compliance
The flip side of inconsistency is overzealousness. Some institutions, wary of regulatory scrutiny or motivated by institutional risk aversion, impose requirements that go well beyond what federal regulations actually demand. On the animal research side, an institution may layer on additional procedural requirements, reporting burdens, or facility standards that provide no material benefit to the animals involved but significantly slow down the research.12ILAR Journal. Avoiding an Overzealous Approach: A Perspective on Regulatory Burden
This problem is not unique to animal oversight. Across the full landscape of research compliance, including human subject protection, biohazard management, export controls, and financial oversight, institutions sometimes attempt to eliminate all conceivable risk regardless of cost. In doing so, they can lose the balance between protecting subjects and enabling the research that creates new treatments and knowledge.12ILAR Journal. Avoiding an Overzealous Approach: A Perspective on Regulatory Burden A researcher who spends months navigating bureaucratic requirements that do not actually improve safety for participants or animals is a researcher who is not generating data that might help patients. The cost of over-compliance is invisible because it is measured in studies delayed, simplified to avoid regulatory hassle, or never attempted at all.
Cross-Border Research and Contextual Gaps
A growing share of clinical research funded by U.S. institutions takes place in low- and middle-income countries, where populations may have limited access to healthcare and where the research infrastructure looks very different from what exists in Boston or San Francisco. U.S. IRBs reviewing these studies face a genuine challenge: they are tasked with interpreting and applying ethical principles and regulations that were developed for the American context in settings where economic disparities, health-system differences, and limited local knowledge make straightforward application difficult.13PubMed Central. US IRBs confronting research in the developing world
Consider the standard of care requirement. If a trial tests a new treatment against the best available therapy, what counts as “best available” in a country where patients have no access to first-line treatments? Should a placebo arm be acceptable when participants would not have access to the active treatment outside the trial anyway? These questions do not have clean answers, and an IRB sitting thousands of miles from the study site may not have the contextual knowledge to answer them well. Some institutions address this by partnering with local ethics committees, but the quality and independence of those committees varies enormously across countries.
Big Data, AI, and the Limits of Existing Frameworks
The regulatory frameworks governing IRBs were designed for a world where research meant enrolling identifiable individuals into defined studies. That world is rapidly being overtaken by one in which researchers analyze massive datasets, sometimes millions of health records, using artificial intelligence and machine-learning tools. The traditional model asks: does this individual participant face risk? But big data research can cause harm to groups, such as racial or socioeconomic communities, without any individual being directly contacted or enrolled.
Current regulations may not permit IRBs to conduct comprehensive review of research that could result in this kind of group harm.14PubMed. Big Health Data Research and Group Harm: The Scope of IRB Review An algorithm trained on biased health data might produce findings that reinforce racial disparities in treatment, or an insurance company might use the results of a big-data study to justify discriminatory pricing. These harms do not fit neatly into the Belmont Report’s framework, which was designed to protect individuals from direct physical or psychological risk. Whether and how IRBs should expand their scope to address these newer forms of harm is an active debate, and one that current regulations do not clearly resolve.
Transparency and Public Trust in Animal Research
IACUCs operate in a space that attracts more public controversy than most IRB work, because a significant portion of the public is uncomfortable with the use of animals in research. The question of how transparent institutions should be about what happens in their animal facilities is not simple. Full transparency sounds appealing, but every story told about laboratory animals involves editorial choices about which images and details to include and which to leave out. Research advocates sharing their stories must decide what to emphasize, and different audiences, from fellow scientists to animal welfare advocates to legislators, may need very different kinds of information to form fair judgments.15PubMed Central. Open Transparent Communication about Animals in Laboratories: Dialog for Multiple Voices and Multiple Audiences
In recent years, there has been a growing movement among research institutions toward greater openness about animal use, including publishing annual statistics on the number and species of animals used, describing the types of procedures performed, and explaining the oversight process. Some institutions have created public-facing videos and facility tours. The tension is real, though: too little transparency feeds suspicion, while selective transparency can feel like public relations rather than genuine accountability. IACUCs are increasingly part of this conversation, both as the committees responsible for ensuring humane treatment and as the bodies whose decisions the public wants to understand.
For researchers navigating these systems, the practical reality is that IRB and IACUC review is not going away, and the scope of what these committees oversee is expanding rather than contracting. The committees are imperfect, sometimes frustratingly so, but the history that created them remains vivid enough to remind everyone why the alternative, trusting researchers to police themselves with no external check, has already been tried and failed.